Safety and efficacy of nivolumab plus ipilimumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase 3b/4 CheckMate 920 trial

BACKGROUND: CheckMate 920 (NCT02982954) is a multicohort, phase 3b/4 clinical trial of nivolumab plus ipilimumab treatment in predominantly US community-based patients with previously untreated advanced renal cell carcinoma (RCC) and clinical features mostly excluded from phase 3 trials. We report s...

Descripción completa

Detalles Bibliográficos
Autores principales: Tykodi, Scott S, Gordan, Lucio N, Alter, Robert S, Arrowsmith, Edward, Harrison, Michael R, Percent, Ivor, Singal, Rakesh, Van Veldhuizen, Peter, George, Daniel J, Hutson, Thomas, Zhang, Joshua, Zoco, Jesus, Johansen, Jennifer L, Rezazadeh Kalebasty, Arash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883262/
https://www.ncbi.nlm.nih.gov/pubmed/35210307
http://dx.doi.org/10.1136/jitc-2021-003844

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883262/
https://www.ncbi.nlm.nih.gov/pubmed/35210307
http://dx.doi.org/10.1136/jitc-2021-003844

Ejemplares similares